New Study Shows Positive Results with Bone Marrow Concentrate (BMC) Injection for Knee Osteoarthritis

Feb 3

New Study Shows Positive Results with Bone Marrow Concentrate (BMC) Injection for Knee Osteoarthritis

Bone Marrow Concentrate (BMC) has evolved in recent years as a one of the most promising orthobiologic therapies for Osteoarthritis (OA). The anti inflammatory and regenerative properties of BMC have been shown in early studies to relieve pain and stiffness, as well as improve joint function, in patients suffering from degenerative arthritis. New studies and clinical trials are constantly emerging, adding more evidence supporting BMC use in OA.

The most recent study, published online from the European Journal of Surgery and Traumatology evaluated 41 patients (75 knees) with a mean age of 60.7 years old, diagnosed with degenerative arthritis, who underwent intra articular injection of BMC with adipose tissue. Each patient was assigned a radiologic arthritis score (I-IV) via the Kellgren-Lawrence grading scale, and Pre/Post operative Visual Analogue Score (VAS) and functional scores were used for evaluation at 3, 6, and 12 months.

The study revealed a decrease in the mean VAS from 7.0 preoperatively to 4.1, 3.5, and 3.3 at the 3, 6, and 12 months follow up appointments. Functional improvements were also illustrated via the International Knee Documentation Committee score, SF-36 score, Knee and Osteoarthitis Outcome score, and the Lysholm Knee Questionnaire. However, when the results were classified based on specific radiologic arthritis grade, Grade IV (severe arthritis) had a significantly less decreases in VAS in comparison to grades I-III, with a preoperative value of 8.2, and 5.5, 5.3, 5.7 in the respective follow ups.

The results contribute to the growing research trends supporting the treatment of OA with intra articular injections of BMC. Given the decreased improvements in Grade IV arthritis patients, this study suggests BMC to be more effective in early to moderate phases of degenerative arthritis. Although, further studies are needed to more thoroughly evaluate the efficacy of BMC therapy, this study adds further support to the regenerative potential of Bone Marrow for degenerative joint diseases such as arthritis.

View Abstract: http://link.springer.com/article/10.1007/s00590-013-1393-9

For more of the latest research in osteoarthritis and bone marrow concentrate therapy, attend the Orthobiologic Institute (TOBI) 5th annual PRP and Regenerative Medicine Symposium in Las Vegas NV June 6-7, 2013. Many thought leaders will be in attendance to help advance our understanding of biologic based therapies. www.prpseminar.com

Leave a Reply

Your email address will not be published. Required fields are marked *